The global allergy immunotherapies market is expected to grow at a CAGR of 7.3% during the period 2015-2020. In 2015, Europe dominated the market, with Germany and France being the major contributors; a trend that is expected to continue during the forecast period. The market in Europe is characterized by approximately 1.3 million individuals eligible for allergy immunotherapy (AIT). Growth across Europe is attributable to the presence of approved SCIT products, such as Grazax. As a result, the SCIT/SLIT drop in the region accounted for 92% of the market share while SLITT accounted for only 8% in 2015. Further, the recent approval of Acarizax in 11 European countries, such as Germany, Italy, France, the UK, and Spain, will likely drive the market. Europe was followed by North America and ROW in terms of market share.

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market Overview

Assumptions

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Allergies: Overview

Prevalence of allergic diseases

PART 06: Pipeline analysis

PART 07: Market landscape

Market overview

Five forces analysis

PART 08: Market segmentation by product type

Global SCIT market

Global SLITD market

Global SLITT market

PART 09: Geographical segmentation

Allergy immunotherapies market in Europe

Allergy immunotherapies market in Germany

Allergy immunotherapies market in France

Allergy immunotherapies market in North America

Allergy immunotherapies market in US

Allergy immunotherapies market in ROW

PART 10: Market drivers

Presence of high unmet medical needs

Existence of novel molecules in pipeline

Increasing prevalence of allergic rhinitis and asthma

coupled with high consumption of tobacco

Upsurge of allergies due to increase in environmental

pollution

PART 11: Impact of drivers

PART 12: Market challenges

Increased preference for CAM

Poor patient adherence and high dropout rates

High cost of allergic immunotherapy

PART 13: Impact of drivers and challenges

PART 14: Market trends

Emergence of SLITT

Advent of SPIRE

Strategic alliances for novel drug developments

Identification of new allergen targets

PART 15: Vendor landscape

Competitive scenario

ALK-Abello

Stallergenes

Merck Group

Allergy Therapeutics

Other prominent vendors

PART 16: Appendix

List of abbreviations

PART 17: Explore Technavio